verapamil has been researched along with fluconazole in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 16 (59.26) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Pratim Roy, P; Roy, K | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bettis, S; Brun, R; Fomovska, A; Huang, Q; Kaiser, M; Kozikowski, AP; McLeod, R; Mui, E; Pieroni, M; Stec, J; Witola, WH | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aguilera-Venegas, B; Bloomer, WD; Chatelain, E; Ioset, JR; Kaiser, M; Lepesheva, GI; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Crego, AL; Gómez, J; Lavandera, JL; Marina, ML | 1 |
| Boulenc, X; Hachad, H; Levy, RH; Ragueneau-Majlessi, I; Rauch, C | 1 |
| Cabrera, JL; Calise, M; Diez, RA; Fornari, MC; Ortega, MG; Peralta, MA; Pérez, C | 1 |
| Cheng, X; Ding, X; Li, M; Qian, K; Xing, L; Xu, N; Yu, Q; Zhang, B | 1 |
| Alnajjar, LM; Bulatova, NR; Darwish, RM | 1 |
| Borowicz, SM; Clemes Külkamp-Guerreiro, I; da Rosa Monte Machado, G; Domingues Bianchin, M; Meneghello Fuentefria, A; Pippi, B; Raffin Pohlmann, A; Stanisçuaski Guterres, S | 1 |
| de Albuquerque, MC; Goldman, GH; Mima, EGO; Pavarina, AC; Vega-Chacón, Y | 1 |
1 review(s) available for verapamil and fluconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
26 other study(ies) available for verapamil and fluconazole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.
Topics: Antimalarials; Benzamides; Imides; Leishmania donovani; Parasitic Sensitivity Tests; Plasmodium falciparum; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma; Trypanosoma brucei rhodesiense; Trypanosoma cruzi | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
Topics: Amides; Animals; Cell Line; Chagas Disease; Dose-Response Relationship, Drug; Methanol; Mice; Mice, Inbred BALB C; Molecular Structure; Parasitic Sensitivity Tests; Rats; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Trypanosoma cruzi | 2015 |
Application of capillary zone electrophoresis with off-line solid-phase extraction to in vitro metabolism studies of antifungals.
Topics: Acetic Acid; Acetonitriles; Antifungal Agents; Clotrimazole; Drug Stability; Electrophoresis, Capillary; Fluconazole; Humans; Itraconazole; Ketoconazole; Methanol; Microsomes, Liver; Molecular Structure; Molecular Weight; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Solvents; Triazoles; Verapamil; Voriconazole | 2001 |
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Erythromycin; Fluconazole; Ketoconazole; Midazolam; Substrate Specificity; Verapamil | 2007 |
A prenylated flavanone from Dalea elegans inhibits rhodamine 6 G efflux and reverses fluconazole-resistance in Candida albicans.
Topics: Antifungal Agents; Candida albicans; Colony Count, Microbial; Drug Resistance, Fungal; Fabaceae; Flavanones; Fluconazole; Fungal Proteins; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Microbial Sensitivity Tests; Plant Components, Aerial; Plant Roots; Prenylation; Rhodamines; Verapamil | 2012 |
In vitro activity of verapamil alone and in combination with fluconazole or tunicamycin against Candida albicans biofilms.
Topics: Antifungal Agents; Biofilms; Candida albicans; Drug Synergism; Fluconazole; Humans; Microbial Sensitivity Tests; Tunicamycin; Verapamil | 2013 |
Evaluation of four calcium channel blockers as fluconazole resistance inhibitors in Candida glabrata.
Topics: Calcium Channel Blockers; Candida glabrata; Diltiazem; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Drug Synergism; Fluconazole; Microbial Sensitivity Tests; Microbial Viability; Nicardipine; Nifedipine; Verapamil | 2018 |
Lipid core nanoparticles as a broad strategy to reverse fluconazole resistance in multiple Candida species.
Topics: Antifungal Agents; ATP-Binding Cassette Transporters; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Caprylates; Delayed-Action Preparations; Drug Compounding; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Gene Expression; Genes, MDR; Hexoses; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Nanoparticles; Palmitates; Particle Size; Triglycerides; Verapamil | 2019 |
Verapamil inhibits efflux pumps in
Topics: Animals; Antifungal Agents; Biofilms; Biological Transport; Candida albicans; Candidiasis; Drug Synergism; Fluconazole; Larva; Membrane Transport Proteins; Microbial Sensitivity Tests; Moths; Verapamil | 2021 |